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An update of the diagnostic guidance document for Clostridium difficile infection (CDI) 21 
issued by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 22 
[1] was recently reviewed by Gateau et al., [2]. The aim of these publications was to optimize 23 
and improve CDI laboratory diagnostic on a global level by defining sample selection, testing 24 
algorithms and the interpretation of laboratory results [1,2]. We highlight some recently 25 
identified pitfalls that do not affect CDI laboratory diagnosis overall, but could have a 26 
significant impact on individual patients. 27 
An unusual Clostridium difficile phenotype on chromogenic selective medium  28 
To speed up the identification of cultured C. difficile strains, a chromogenic agar was 29 
developed (ChromID® agar, bioMérieux).  However, as was recently shown for strains from 30 
Spain and Northern Ireland, isolates of PCR ribotype 023 may fail to produce black colonies, 31 
a presumptive identification of C. difficile [3,4], because C. difficile PCR ribotype 023 strains 32 
cannot hydrolyse esculin [3].  The C. difficile PCR ribotype 023 was one of the ten most 33 
frequent ribotypes identified in Eastern and Western Europe during 2012-2013 [5], which 34 
highlights the need for awareness among clinical microbiologists that PCR ribotype 023 35 
strains produce atypical (colourless) colonies on ChromID® agar (bioMérieux). 36 
Toxin A/B negativity in Clostridium difficile strains that are only binary toxin gene-positive  37 
The clinical significance of C. difficile PCR ribotype 033 in humans was recently reported in 38 
Australia, France and Italy [6-8].  PCR ribotype 033 clusters with ribotypes 045, 066, 078, 39 
126 and 193 in sequence type 11 [9] and encodes binary toxin genes, but also contains a 40 
truncated pathogenicity locus (part of tcdA gene); however, neither of the large clostridial 41 
toxins are produced, [10] and thus this ribotype cannot be detected by commercial tests for the 42 
detection of free toxins A/B in faeces. Depending on the chosen primers, nucleic acid 43 
amplification tests (NAATs) can reveal a positive result for the detection of binary toxin 44 
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gene(s) and/or for the presence of tcdA gene, but this information is lacking for most of the 45 
commercially available NAATs.  While PCR ribotype 033 CDI did not result in diarrhoea and 46 
death in a hamster model, [11] there is evidence for its ability to cause CDI in humans [6-8]. 47 
PCR ribotype 033 has also been recovered from domestic animals and livestock [12,13]. 48 
Furthermore, a newly described four-gene insertion, which affects trehalose metabolism and 49 
may be associated with increased virulence, has been found only in a few C. difficile PCR 50 
ribotypes, including 033 [14]. These observations mean that further research is needed on the 51 
role of PCR ribotype 033 in human CDI. 52 
Glutamate dehydrogenase negative and toxin A/B positive results from diagnostic assays 53 
The simultaneous detection of glutamate dehydrogenase (GDH) and toxins A/B by enzyme 54 
immunoassays, which include both of these targets in one assay, is an alternative to a two-step 55 
CDI testing algorithm. A GDH negative and toxin A/B positive test result is considered as 56 
invalid, with a need for stool sample retesting [1,2]. We have confirmed that five stool 57 
samples, sent from different Czech hospitals, repeatedly showed such GDH negative and 58 
toxin A/B positive test results. However, when these five stool samples were anaerobically 59 
cultured, the C. difficile colonies tested were positive for both GDH and toxins A/B with the 60 
same combined assay. Moreover, PCR ribotyping of the cultured C. difficile colonies revealed 61 
five different PCR ribotypes (012, 014, 020, 070 and 176). Although there is no explanation at 62 
present for the failure to detect GDH, it suggests a third diagnostic step may be needed in 63 
order to confirm a GDH negative toxin A/B positive result. 64 
The inaccuracy of molecular methods for detecting epidemic PCR ribotype 027  65 
NAATs that target tcdB or tcdA of toxigenic C. difficile, are an alternative first step option in 66 
CDI diagnostics due to their high negative predictive value.  NAATs can also be used as a 67 
third step option to distinguish toxigenic from non-toxigenic C. difficile strains in GDH 68 
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positive and free toxin A/B negative stool samples [1,2]. Some NAATs (e.g. Xpert® C. 69 
difficile (Cepheid), GenoType® Cdiff, (Hain Lifescience), Verigene C. difficile Test, 70 
(Nanosphere)) can also detect the binary toxin gene(s) (cdtA/cdtB) and the specific deletion at 71 
position 117 of the tcdC gene, which is assumed to indicate the presence of C. difficile PCR 72 
ribotype 027. However, this marker has recently been identified in other PCR ribotypes [15]. 73 
Thus, the interpretation of “presumptive ribotype 027 positive” results should be correlated 74 
with the local-CDI epidemiology. Definitive ribotype identification requires capillary 75 
electrophoresis-based PCR ribotyping. 76 
Negative diagnostic tests for CDI in patients with endoscopically confirmed 77 
pseudomembranous colitis. 78 
Though most frequently associated with CDI, a wide differential diagnosis should be 79 
considered when pseudomembranous colitis is diagnosed endoscopically and laboratory tests 80 
are negative. Other bacterial, viral, and parasitic pathogens have also been implicated in 81 
pseudomembranous colitis including Escherichia coli O157:H7, cytomegalovirus and 82 
Entamoeba histolytica. Additionally, the pseudomembranous colitis can occur in 83 
inflammatory bowel diseases, ischemic colitis and also can be caused by several chemicals 84 
such as cisplatin and cyclosporine A [16]. 85 
There is a wide choice of assays available to facilitate the rapid laboratory diagnosis of CDI. 86 
It is crucial, however, that microbiology laboratories select appropriate test combinations to 87 
optimise CDI diagnosis and provide clear local guidance on sample selection for CDI testing 88 
[1,2]. Furthermore, given the complexity of CDI diagnosis, the interpretation and 89 
communication of test results is at least as important as the result itself. In the case of an 90 
inconclusive test result, particularly when associated with unwell patients or if sub-optimal 91 
assay performance is suspected, the national reference or central laboratory for C. difficile 92 
should be contacted. 93 
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